Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS
Authors:
- 1 April 2017
- journal article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 43, 60-67
Abstract
No abstract availableKeywords
Funding Information
- Almirall S.A. (IDI-20130948)
- Centre for Technological and Industrial Development (CDTI)
This publication has 38 references indexed in Scilit:
- Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in HumansPLOS ONE, 2013
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated DiseaseImmunity, 2012
- Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant RejectionJournal of Medicinal Chemistry, 2010
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritisJournal of Inflammation, 2010
- The JAK-STAT Signaling Pathway: Input and Output IntegrationThe Journal of Immunology, 2007
- Human Tyrosine Kinase 2 Deficiency Reveals Its Requisite Roles in Multiple Cytokine Signals Involved in Innate and Acquired ImmunityImmunity, 2006
- Regulation of cytokine signaling pathways by PIAS proteinsCell Research, 2006
- The Janus kinases (Jaks)Genome Biology, 2004
- The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine ModelsAmerican Journal of Transplantation, 2004
- Janus kinase 3 (Jak3) is essential for common cytokine receptor γ chain (γc)-dependent signaling: comparative analysis of γc, Jak3, and γc and Jak3 double-deficient miceInternational Immunology, 2000